- Home
- TRIN vs MDXG Comparison
TRIN vs MDXG Comparison
Compare TRIN & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- MDXG
- Stock Information
- Founded
- TRIN 2007
- MDXG 2006
- Country
- TRIN United States
- MDXG United States
- Employees
- TRIN N/A
- MDXG N/A
- Industry
- TRIN Finance/Investors Services
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- TRIN Finance
- MDXG Health Care
- Exchange
- TRIN Nasdaq
- MDXG Nasdaq
- Market Cap
- TRIN 912.3M
- MDXG 999.9M
- IPO Year
- TRIN 2021
- MDXG N/A
- Fundamental
- Price
- TRIN $14.27
- MDXG $5.81
- Analyst Decision
- TRIN Hold
- MDXG Strong Buy
- Analyst Count
- TRIN 3
- MDXG 2
- Target Price
- TRIN $14.83
- MDXG $12.50
- AVG Volume (30 Days)
- TRIN 667.9K
- MDXG 505.5K
- Earning Date
- TRIN 08-06-2025
- MDXG 07-30-2025
- Dividend Yield
- TRIN 14.30%
- MDXG N/A
- EPS Growth
- TRIN 37.77
- MDXG N/A
- EPS
- TRIN 2.19
- MDXG 0.27
- Revenue
- TRIN $240,010,000.00
- MDXG $352,375,000.00
- Revenue This Year
- TRIN $24.11
- MDXG $9.55
- Revenue Next Year
- TRIN $4.87
- MDXG $11.43
- P/E Ratio
- TRIN $6.52
- MDXG $21.73
- Revenue Growth
- TRIN 30.65
- MDXG 5.34
- 52 Week Low
- TRIN $12.50
- MDXG $5.47
- 52 Week High
- TRIN $16.82
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- TRIN 40.55
- MDXG 30.41
- Support Level
- TRIN $14.18
- MDXG $5.80
- Resistance Level
- TRIN $14.62
- MDXG $6.03
- Average True Range (ATR)
- TRIN 0.20
- MDXG 0.19
- MACD
- TRIN -0.03
- MDXG -0.05
- Stochastic Oscillator
- TRIN 13.56
- MDXG 2.47
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.